NGM Biopharmaceuticals In... (NGM)
NASDAQ: NGM
· Real-Time Price · USD
1.54
-0.02 (-1.28%)
At close: Apr 03, 2024, 3:59 PM
NGM Biopharmaceuticals Balance Sheet Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Cash & Equivalents | 58.81M | 51.48M | 53.27M | 67.55M | 73.46M | 101.45M | 63.38M | 109.87M | 151.79M | 145.83M | 99.4M | 148.11M |
Short-Term Investments | 88.37M | 114.57M | 140.27M | 163.46M | 198.04M | 198.7M | 234.43M | 219.96M | 214.46M | 237.6M | 291.15M | 264.54M |
Long-Term Investments | 2.46M | 2.46M | 2.46M | 2.46M | 3.95M | 3.95M | 1.5M | n/a | n/a | n/a | n/a | n/a |
Other Long-Term Assets | 2.94M | 4.84M | 4.86M | 4.3M | 4M | 5.3M | 5.47M | 9.14M | 8.99M | 8.52M | 7.09M | 5.96M |
Receivables | 58K | n/a | 736K | 1.26M | 7.58M | 4.38M | 6.67M | 103K | 4.95M | 4.4M | 3.59M | 4.92M |
Inventory | n/a | n/a | 1.5M | 1.5M | n/a | n/a | n/a | n/a | -4.95M | n/a | n/a | n/a |
Other Current Assets | 9.2M | 7.99M | 8.62M | 8.77M | 9.79M | 11.17M | 14.36M | 7.69M | 8.08M | 8.05M | 8.99M | 8.27M |
Total Current Assets | 156.44M | 177.04M | 204.4M | 242.53M | 288.86M | 315.7M | 318.84M | 337.62M | 379.28M | 395.88M | 403.13M | 425.85M |
Property-Plant & Equipment | 7.03M | 7.82M | 8.83M | 9.55M | 10.59M | 10.92M | 11.57M | 13.01M | 14.12M | 11.45M | 12.79M | 13.73M |
Goodwill & Intangibles | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Total Long-Term Assets | 12.42M | 15.11M | 16.14M | 16.31M | 18.54M | 20.17M | 18.53M | 22.15M | 23.11M | 19.98M | 19.88M | 19.69M |
Total Assets | 168.87M | 192.15M | 220.54M | 258.84M | 307.4M | 335.87M | 337.37M | 359.77M | 402.39M | 415.86M | 423.01M | 445.54M |
Account Payables | 2.98M | 4.69M | 5.86M | 13.29M | 8.45M | 3.56M | 6.87M | 4.82M | 5.25M | 7.63M | 5.14M | 7.54M |
Deferred Revenue | n/a | 107K | 689K | 376K | 366K | 6.97M | 6.5M | 5.12M | 17.77M | 12.29M | 4.96M | n/a |
Short-Term Debt | n/a | 1.38M | 2.75M | 4.07M | 5.38M | 5.31M | 5.23M | 5.15M | 5.08M | n/a | n/a | n/a |
Other Current Liabilities | 17.1M | 16.17M | 19.13M | 20.16M | 33.64M | 32.76M | 23.94M | 29.48M | 33.26M | 37.81M | 34.94M | 32.77M |
Total Current Liabilities | 20.08M | 22.34M | 28.42M | 37.9M | 47.84M | 48.6M | 42.54M | 44.56M | 61.35M | 57.73M | 45.04M | 40.31M |
Long-Term Debt | n/a | n/a | n/a | n/a | n/a | 1.38M | 2.75M | 4.07M | 5.38M | n/a | n/a | n/a |
Other Long-Term Liabilities | 149K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 4.09M | 4.89M | 5.66M |
Total Long-Term Liabilities | 149K | n/a | n/a | 17.37M | 14.2M | 1.38M | 2.75M | 4.07M | 5.38M | 4.09M | 4.89M | 5.66M |
Total Liabilities | 20.23M | 22.34M | 28.42M | 37.9M | 47.84M | 49.98M | 45.29M | 48.64M | 66.74M | 61.82M | 49.94M | 45.96M |
Total Debt | n/a | 1.38M | 2.75M | 4.07M | 5.38M | 6.69M | 7.98M | 9.23M | 10.46M | n/a | n/a | n/a |
Common Stock | 83K | 83K | 83K | 82K | 82K | 82K | 79K | 78K | 78K | 78K | 77K | 77K |
Retained Earnings | -724.01M | -696.34M | -667.54M | -629.28M | -581.63M | -545.2M | -497.94M | -451.42M | -418.97M | -391.73M | -362.87M | -326.18M |
Comprehensive Income | 18K | -78K | -149K | -97K | -302K | -915K | -1.08M | -677K | -129K | -11K | 5K | -18K |
Shareholders Equity | 148.64M | 169.81M | 192.12M | 220.93M | 259.56M | 285.89M | 292.08M | 311.14M | 335.65M | 354.04M | 373.07M | 399.58M |
Total Investments | 90.82M | 114.57M | 140.27M | 163.46M | 198.04M | 198.7M | 234.43M | 219.96M | 214.46M | 237.6M | 291.15M | 264.54M |